Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 23
Filtrar
1.
Small ; : e2405635, 2024 Sep 30.
Artículo en Inglés | MEDLINE | ID: mdl-39344596

RESUMEN

The increasing incidence of serious bacterial keratitis, a sight-threatening condition often exacerbated by inadequate contact lens (CLs) care, highlights the need for innovative protective technology. This study introduces a long-lasting antibacterial, non-cytotoxic, transparent nanocoating for CLs via a solvent-free polymer deposition method, aiming to prevent bacterial keratitis. The nanocoating comprises stacked polymer films, with poly(dimethylaminomethyl styrene-co-ethylene glycol dimethacrylate) (pDE) as a biocompatible, antibacterial layer atop poly(2,4,6,8-tetramethyl-2,4,6,8-tetravinylcyclotetrasiloxane) (pV4D4) as an adhesion-promoting layer. The pD6E1-grafted (g)-pV4D4 film shows non-cytotoxicity toward two human cell lines and antibacterial activity of >99% against four bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), an antibiotic-resistant bacteria and Pseudomonas aeruginosa, which causes ocular diseases. Additionally, the film demonstrates long-lasting antibacterial activity greater than 96% against MRSA for 9 weeks in phosphate-buffered saline. To the best knowledge, this duration represents the longest reported long-term stability with less than 5% decay of antibacterial performance among contact-killing antibacterial coatings. The film exhibits exceptional mechanical durability, retaining its antibacterial activity even after 15 washing cycles. The pD6E1-g-pV4D4-coated CL maintains full optical transmittance compared to that of pristine CL. It is expected that the unprecedentedly prolonged antibacterial performance of the coating will significantly alleviate the risk of infection for long-term CL users.

2.
Semin Immunol ; 34: 25-32, 2017 12.
Artículo en Inglés | MEDLINE | ID: mdl-28985993

RESUMEN

Engineered nanoparticles (NPs) have broad applications in industry and nanomedicine. When NPs enter the body, interactions with the immune system are unavoidable. The innate immune system, a non-specific first line of defense against potential threats to the host, immediately interacts with introduced NPs and generates complicated immune responses. Depending on their physicochemical properties, NPs can interact with cells and proteins to stimulate or suppress the innate immune response, and similarly activate or avoid the complement system. NPs size, shape, hydrophobicity and surface modification are the main factors that influence the interactions between NPs and the innate immune system. In this review, we will focus on recent reports about the relationship between the physicochemical properties of NPs and their innate immune response, and their applications in immunotherapy.


Asunto(s)
Sistema Inmunológico , Inmunoterapia/métodos , Nanopartículas/metabolismo , Animales , Ingeniería Genética , Humanos , Inmunidad Innata , Nanomedicina , Nanopartículas/química
3.
Anal Chem ; 92(2): 2011-2018, 2020 01 21.
Artículo en Inglés | MEDLINE | ID: mdl-31825199

RESUMEN

Nanomaterial-based drug delivery vehicles are able to deliver therapeutics in a controlled, targeted manner. Currently, however, there are limited analytical methods that can detect both nanomaterial distributions and their biochemical effects concurrently. In this study, we demonstrate that matrix assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI) and laser ablation inductively coupled plasma mass spectrometry imaging (LA-ICP-MSI) can be used together to obtain nanomaterial distributions and biochemical consequences. These studies employ nanoparticle-stabilized capsules (NPSCs) loaded with siRNA as a testbed. MALDI-MSI experiments on spleen tissues from intravenously injected mice indicate that NPSCs loaded with anti-TNF-α siRNA cause changes to the lipid composition in white pulp regions of the spleen, as anticipated, based on pathways known to be affected by TNF-α, whereas NPSCs loaded with scrambled siRNA do not cause the predicted changes. Interestingly, LA-ICP-MSI experiments reveal that the NPSCs primarily localize in the red pulp, suggesting that the observed changes in lipid composition are due to diffusive rather than localized effects on TNF-α production. Such information is only accessible by combining data from the two modalities, which we accomplish by using the heme signals from MALDI-MSI and iron signals from LA-ICP-MSI to overlay the images. Several unexpected changes in lipid composition also occur in regions where the NPSCs are found, suggesting that the NPSCs themselves can influence tissue biochemistry as well.


Asunto(s)
Cápsulas/análisis , Nanopartículas/análisis , Bazo/química , Animales , Cápsulas/administración & dosificación , Cápsulas/metabolismo , Portadores de Fármacos/administración & dosificación , Portadores de Fármacos/análisis , Portadores de Fármacos/metabolismo , Inyecciones Intravenosas , Espectrometría de Masas , Ratones , Nanopartículas/administración & dosificación , Nanopartículas/metabolismo , Bazo/metabolismo , Distribución Tisular
4.
Pharmacol Res ; 148: 104452, 2019 10.
Artículo en Inglés | MEDLINE | ID: mdl-31518642

RESUMEN

Immunotherapy has become a promising new approach for cancer treatment due to the immune system's ability to remove tumors in a safe and specific manner. Many tumors express anti-inflammatory factors that deactivate the local immune response or recruit peripheral macrophages into pro-tumor roles. Because of this, effective and specific ways of activating macrophages into anti-tumor phenotypes is highly desirable for immunotherapy purposes. Here, the use of a small molecule TLR agonist as a macrophage activator for anti-cancer therapy is reported. This compound, referred to as PBI1, demonstrated unique activation characteristics and expression patterns compared to treatment with LPS, through activation of TLR4. Furthermore, PBI1 treatment resulted in anti-tumor immune behavior, enhancing macrophage phagocytic efficiency five-fold versus non-treated macrophages. Additive effects were observed via use of a complementary strategy (anti-CD47 antibody), resulting in ∼10-fold enhancement of phagocytosis, suggesting this small molecule approach could be used in conjunction with other therapeutics.


Asunto(s)
Antineoplásicos/farmacología , Indoles/farmacología , Activación de Macrófagos/efectos de los fármacos , Macrófagos/efectos de los fármacos , Animales , Antígeno CD47/metabolismo , Línea Celular , Inmunoterapia/métodos , Macrófagos/metabolismo , Ratones , Fagocitosis/efectos de los fármacos , Células RAW 264.7 , Bibliotecas de Moléculas Pequeñas/farmacología
5.
Chem Soc Rev ; 47(10): 3421-3432, 2018 May 21.
Artículo en Inglés | MEDLINE | ID: mdl-29537040

RESUMEN

The delivery of proteins into cells is a potential game changer for a wide array of therapeutic purposes, including cancer therapy, immunomodulation and treatment of inherited diseases. In this review, we present recently developed nanoassemblies for protein delivery that utilize strategies that range from direct assembly, encapsulation and composite formation. We will discuss factors that affect the efficacy of nanoassemblies for delivery from the perspective of both nanoparticles and proteins. Challenges in the field, particularly achieving effective cytosolar protein delivery through endosomal escape or evasion are discussed.


Asunto(s)
Nanopartículas/metabolismo , Proteínas/metabolismo , Línea Celular , Humanos , Sustancias Macromoleculares/síntesis química , Sustancias Macromoleculares/química , Sustancias Macromoleculares/metabolismo , Nanopartículas/química , Proteínas/química
6.
Bioconjug Chem ; 29(2): 445-450, 2018 02 21.
Artículo en Inglés | MEDLINE | ID: mdl-29298051

RESUMEN

We present here an integrated nanotechnology/biology strategy for cancer immunotherapy that uses arginine nanoparticles (ArgNPs) to deliver CRISPR-Cas9 gene editing machinery into cells to generate SIRP-α knockout macrophages. The NP system efficiently codelivers single guide RNA (sgRNA) and Cas9 protein required for editing to knock out the "don't eat me signal" in macrophages that prevents phagocytosis of cancer cells. Turning off this signal increased the innate phagocytic capabilities of the macrophages by 4-fold. This improved attack and elimination of cancer cells makes this strategy promising for the creation of "weaponized" macrophages for cancer immunotherapy.


Asunto(s)
Sistemas CRISPR-Cas , Edición Génica/métodos , Macrófagos/metabolismo , Receptores Inmunológicos/genética , Animales , Repeticiones Palindrómicas Cortas Agrupadas y Regularmente Espaciadas , Técnicas de Inactivación de Genes/métodos , Humanos , Inmunoterapia/métodos , Macrófagos/inmunología , Ratones , Nanomedicina/métodos , Neoplasias/inmunología , Neoplasias/terapia , Fagocitosis , Células RAW 264.7 , Receptores Inmunológicos/inmunología
7.
Chemistry ; 24(35): 8717-8726, 2018 Jun 21.
Artículo en Inglés | MEDLINE | ID: mdl-29543990

RESUMEN

The accumulation of therapeutic and imaging agents at sites of interest is critical to their efficacy. Similarly, off-target effects (especially toxicity) are a major liability for these entities. For this reason, the use of delivery vehicles to improve the distribution characteristics of bio-active agents has become ubiquitous in the field. However, the majority of traditionally employed, cargo-bearing platforms rely on passive accumulation. Even in cases where "targeting" functionalities are used, the agents must first reach the site in order for the ligand-receptor interaction to occur. The next stage of vehicle development is the use of "recruited" entities, which respond to biological signals produced in the tissues to be targeted, resulting in improved specificities. Recently, many advances have been made in the utilization of cells as delivery agents. They are biocompatible, exhibit excellent circulation lifetimes and tissue penetration capabilities, and respond to chemotactic signals. In this Minireview, we will explore various cell types, modifications, and applications where cell-based delivery agents are used.


Asunto(s)
Portadores de Fármacos/química , Eritrocitos , Leucocitos , Macrófagos , Materiales Biocompatibles , Transporte Biológico , Medios de Contraste/administración & dosificación , Liberación de Fármacos , Colorantes Fluorescentes/administración & dosificación , Humanos , Nanopartículas
8.
Small ; 12(28): 3775-9, 2016 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-27295172

RESUMEN

A co-engineered nanoparticle/protein peroxide detector is created. This system features a gold nanoparticle functionalized with a galactose headgroup (AuNP-Gal) that reacts covalently with a boronate-modified green fluorescent protein (PB-GFP). Boronate acid-saccharide complexation between PB-GFP and AuNP-Gal affords a highly stable assembly. This complex is disrupted by peroxide, allowing quantitative and selective monitoring of hydrogen peroxide production in real time.


Asunto(s)
Técnicas Biosensibles/métodos , Oro/química , Peróxido de Hidrógeno/química , Nanopartículas del Metal/química , Estrés Oxidativo/fisiología , Galactosa/química , Proteínas Fluorescentes Verdes/química
9.
Nanotechnology ; 27(37): 374001, 2016 Sep 16.
Artículo en Inglés | MEDLINE | ID: mdl-27505356

RESUMEN

We report on nanoparticle-stabilized capsules (NPSCs) as a platform for the co-delivery of survivin-targeted siRNA and tamoxifen. These capsules feature an inner oil core that provides a carrier for tamoxifen, and is coated on the surface with positively charged nanoparticles self-assembled with siRNA. The multifaceted chemical nature of the NPSC system enables the simultaneous delivery of both payloads directly into the cytosol in vitro. The NPSC co-delivery of tamoxifen and survivin-targeted siRNA into breast cancer cells disables the pathways that inhibit apoptosis, resulting in enhanced breast cell death.


Asunto(s)
Nanopartículas , Citosol , Proteínas Inhibidoras de la Apoptosis , Nanocápsulas , ARN Interferente Pequeño
10.
Bioconjug Chem ; 25(9): 1602-8, 2014 Sep 17.
Artículo en Inglés | MEDLINE | ID: mdl-25133522

RESUMEN

The direct delivery of functional proteins into the cell cytosol is a key issue for protein therapy, with many current strategies resulting in endosomal entrapment. Protein delivery to the cytosol is challenging due to the high molecular weight and the polarity of therapeutic proteins. Here we review strategies for the delivery of proteins into cells, including cell-penetrating peptides, virus-like particles, supercharged proteins, nanocarriers, polymers, and nanoparticle-stabilized nanocapsules. The advantages and disadvantages of these approaches including cytosolar delivery are compared and contrasted, with promising pathways forward identified.


Asunto(s)
Sistemas de Liberación de Medicamentos/métodos , Espacio Intracelular/metabolismo , Proteínas/metabolismo , Animales , Humanos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA